HEALTH TECHNOLOGY

FAST+ Solution of CitiusTech to Utilize IBM Cloud Paks to Support Upsurge Healthcare Interoperability

CitiusTech | February 17, 2021

A leading healthcare technology solutions and service provider company, CitiusTech, has announced its adoption of IBM Cloud Paks for powering its FAST+ solution to improve healthcare interoperability. FAST+ solution of CitiusTech is aimed at healthcare organizations’ FHIR-based solution to meet with different interoperability needs, which include Patient Access Rule and compliance to CMS’ Interoperability. From the solution, healthcare organizations get a strong platform for consent management, FHIR data repository, standardize information, and also allows real-time data access.

“We are excited to spread our teamwork with IBM,” said SVP of Partnerships and Strategy at CitiusTech, Manish Sharma. “Our adoption of IBM’s open technology ecosystem pays for better scalability and tractability to our customer’s lasting interoperability requirements.”

CitiusTech is a portion of IBM's cloud Pak ecosystem, an enterprise to support associates of all types to assist clients to accomplish and streamline workloads from bare-metal to multi-cloud with Red Hat OpenShift, the business's leading initiative Kubernetes platform.

CitiusTech is powering Cloud Engagement Fund IBM, recognized as part of IBM's $1 billion assets into its ecosystem, to get technical resources and cloud acclaims to provision migration of client workloads to open hybrid cloud settings, such as IBM Cloud. By means of contributions from IBM Cloud, such as the IBM Kubernetes Service (IKS), the company can advance more value from its information to support speed the growth of new tools intended to improve competence for the manufacturing.

The company has a sturdy digital innovation exercise that emphasizes helping customers assume enterprise-wide change creativities using IBM technology stages including IBM BigInsights, IBM Cloud Pak, IBM Netezza, IBM Unified Data Models, and IBM Cognos Analytics for Healthcare.

About CitiusTech

CitiusTech is a well-known technology for healthcare industry services and various solutions for health tech companies, payers, providers, and life sciences organizations. The company has around 4,000 professionals globally. CitiusTech allows healthcare groups to drive medical value chain superiority.

Spotlight

Global Blockchain in Healthcare Market by Organization Size (Large Enterprises, Small & Medium-sized Enterprises (Sme’s) by Blockchain Type (Public, Private, Hybrid) by Application (Healthcare Data Exchange, Pharmaceuticals Supply Chain, Health Insurance, Drug Discovery, Identity & Authentication, Other Application) & by Geography.


Other News
INSURANCE

As One Insurance Group Launches Population Health Strategy That is Revolutionizing Healthcare

As One Insurance Group | February 25, 2022

Privately-held insurance brokerage firm As One Insurance Group ("As One") has announced the launch of its population health strategy that is already revolutionizing the healthcare industry based in Phoenix, As One has quickly achieved benchmark status in the population health world. Brandon Bullock, Chief Strategy Officer of As One, says, "Over the years we have seen the number of those without access to healthcare shrink, the numbers are a positive sign, 10 percent of Americans still have no access to care. We're looking to close that gap. As One is offering Health Navigator alongside its proprietary sales platform which leverages electronic processing to speed up the sales cycle." The cutting-edge firm specializes in life, health, and ancillary insurance benefits and is making insurance simple for carriers, agents, and clients through distinct offerings including: An innovative population health strategy A proprietary sales platform and CRM for straight-through electronic processing An impressive nationwide distribution channel Advanced agent training and sales tools "With the right tools at their fingertips, our team and agents show tremendous courage every day fighting to fix health insurance, a strong team that works as one." J.R. Jordan, Chief Executive Officer of As One Cost of Healthcare in America The cost of Healthcare in the United States is a significant factor that prevents people from obtaining the necessary care or filling prescriptions. Half of U.S. adults have stated that they postponed or completely mitigated some sort of dental or health care in the past year due to the high cost. Three in 10 people have also reported not taking their necessary medicines as prescribed at some point due to the very same reason. High healthcare costs excessively affect uninsured adults and those with lower household incomes. Larger shares of U.S. adults have also reported difficulty affording different types of care, which further delays and attributes to them forgoing medical care due to the cost. However, individuals that are covered by health insurance are not immune to the weight of healthcare costs. Almost half (46%) of those insured reported difficulty affording out-of-pocket expenses, and 27% had reported difficulty in being able to afford their deductible. Difficulty paying medical bills has resulted in significant consequences for U.S. families. Medical bill problems are also disproportionately affecting those adults in households where they or a member of their household has a severe health condition. About As One Insurance Group As One Insurance Group ("As One") is a privately held insurance brokerage based in Phoenix, Arizona, specializing in life, health, and ancillary insurance benefits. As One aims to simplify insurance by making the process straightforward and honest. With transparent product information and open communications being the norm, the company provides a range of life and health insurance products that are coupled with the tools agents and clients need to manage their needs. That includes advanced education and training, innovative technology solutions, and best-in-class service. In short, they work with and for agents, clients, and carriers together as one.

Read More

MEDICAL DEVICES

Lark Health Builds AI-Driven Heart Health Program

Lark Health | March 17, 2022

Lark Health today announced the development of a novel AI-driven program for the prevention and management of atherosclerotic cardiovascular disease and coronary artery disease in collaboration with Roche Diagnostics. The program, named Lark Heart Health, is an AI-driven virtual care solution that provides personalized health coaching anytime, anywhere. The new Heart Health program is planned to launch later this year. Cardiovascular disease is the leading cause of death globally, and nearly half of all adults in the U.S. have some form of CVD. It's also one of the most expensive chronic conditions, with heart disease and stroke costing the U.S. healthcare system roughly $214 billion annually. Yet, provider shortages and siloed care teams leave patients with limited care options, gaps in care, and insufficient education and empowerment to self-manage their heart health. Additionally, high treatment costs and resource constraints often limit care to those with the highest acuity conditions. Built using a Cognitive Behavioral Therapy framework and designed in accordance with guidelines from the American Heart Association (AHA), Lark Heart Health will provide a cost-effective, scalable solution for continuous, person-centric remote heart health coaching intended to help users improve their healthy lifestyle behaviors, reduce stress levels, and ultimately decrease risk factors for heart disease. Through an evidence-based educational curriculum and real-time personalized coaching, Lark will provide users with the tools they need to make meaningful lifestyle changes that can help them better prevent and manage ASCVD and CAD. Earlier this year, Lark announced it had joined the AHA's Network at American Heart Association Center of Health Technology & Innovation, which is focused on building and fostering health technology relationships to develop innovative and scalable solutions. "Lark Heart Health will help those at high risk prevent and actively manage cardiovascular disease through personalized digital coaching. By leveraging our AI technology, we can deliver meaningful and engaging care at an unprecedented scale, and this collaboration with Roche Diagnostics will support the expansion of our proven tech platform into one of the costliest chronic disease markets." Julia Hu, co-founder and CEO of Lark About Lark Health Lark is a healthcare technology company aimed at delivering infinitely scalable, virtual chronic and preventative healthcare through conversational AI. To date, Lark has provided nearly 2 million people with unlimited, 24/7 personalized care delivered through an easy-to-use, text message-like interface that integrates remote patient monitoring tools and is built on a cognitive behavioral therapy framework. Lark's platform seamlessly integrates with health plans' and employers' existing healthcare infrastructure to help them scale their chronic disease prevention and management programs, boost engagement, and improve health outcomes. Lark currently works with many of the largest health plans and across four programs: Prevention, Diabetes Prevention, Diabetes Care, and Hypertension Care. Lark's Diabetes Prevention Program, which is the fastest growing and lowest cost DPP, has received the highest level of clinical recognition—Full Recognition—from the Centers for Disease Control and Prevention. The company has received numerous accolades, including having been named as one of CB Insights Digital Health 150 (2019), a finalist for the UCSF Digital Health Awards one of Fast Company's Most Innovative Companies and one of Fierce Healthcare's Fierce 15.

Read More

FUTURE OF HEALTHCARE

Endonovo Therapeutics Signs Agreement with NAMSA to Develop Reimbursement Strategy for Endonovo Medical Products

Endonovo Therapeutics, Inc. | April 26, 2022

Endonovo Therapeutics, Inc. announced an agreement with NAMSA – a leading Global Contract Research Organization and medical device reimbursement specialist – as strategic advisors to develop in-patient and out-patient medical reimbursement strategies for Endonovo’s flagship PEMF product SofPulse®. “Engaging NAMSA as strategy advisors to develop and apply proven medical device reimbursement strategies is a huge advantage for Endonovo and our shareholders, according to Endonovo CEO Alan Collier. “NAMSA is a proven medical device development partner with relevant therapeutic know-how that is critical when seeking acceleration of reimbursement efforts and commercialization objectives,” he pointed out. NAMSA was founded in 1967 as a scientific research company and later transitioned into a Global CRO and Medtech (Medical Technologies) reimbursement specialist. Today, it has 1,000 strategic associates who provide Medtech reimbursement advisory expertise to more than 300 clients in 15 global regions. NAMSA offers a full continuum of reimbursement services for medical technologies. Their reimbursement consultants provide: payer relations, medical policy research, coverage advocacy, Healthcare Common Procedure Coding System Current Procedural Terminology code analysis/applications and health economic analysis. “Our team strives to bring impactful products like the Endonovo SofPulse into higher adoption. With this technology, and its favorable economics, there are multiple opportunities ahead for serving populations in need. We will work together with the Endonovo team to improve market access for this novel device in the very near term.”, Joseph Sierra, Director, Reimbursement Consulting, North America, NAMSA NAMSA provides strategic guidance and tactical support to fast-track medical device commercialization and to make an immediate impact on patient healthcare worldwide. NAMSA’s services have grown to include regulatory, reimbursement and quality consulting as well as clinical research. These additions have helped NAMSA to become the pre-eminent 100% medical device-focused Global CRO that offers proven strategic solutions throughout the full development continuum. NAMSA is the only US FDA ASCA accredited medical device biocompatibility laboratory in the world. This allows medical device sponsors to fast-track commercialization efforts, while achieving time and cost efficiencies in every major market of the world. Collier stated: “We are fortunate to be working directly with Joseph Sierra, at NAMSA. With over 10 years of reimbursement experience, and his proven track-record in developing successful medical device reimbursement strategies is exemplary and will be helpful in developing the path toward reimbursement for our main product SofPulse®. Joseph is an adjunct instructor at USC Masters of Health Administration Program, and his prior professional work includes successful stints with NeoFect USA and Medtronic Ltd. where he demonstrated a record of success leading roles in reimbursement programs, analysis, and strategies for their medical devices.” NAMSA’s reimbursement expertise and track-record in the introduction and adoption of medical devices into multiple medical specialties includes: orthopedics, cardiovascular surgery, general surgery, plastic surgery, neurology, robotic surgery and wound care. Collaborating with NAMSA on global reimbursement allows Endonovo to explore reimbursement for the U.S. medical markets as well as the European Union market adoption through SofPulse® medical CE Mark. Additional target markets would be Taiwan and other Asian countries. About Endonovo Therapeutics Inc. Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceuticals® therapeutic devices for pain relief, general wellness and wound curatives. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system disorders, including traumatic brain injury, acute concussions, post-concussion syndrome and multiple sclerosis. The Company's noninvasive Electroceutical® therapeutic device, SofPulse®, which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema. It also has CMS national coverage for the treatment of chronic wounds. The Company's current portfolio of preclinical-stage Electroceuticals® therapeutic devices addresses chronic kidney disease, liver disease, non-alcoholic steatohepatitis cardiovascular and peripheral artery disease and ischemic stroke. The Company's noninvasive, wearable Electroceuticals® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

Read More

FUTURE OF HEALTHCARE

Kubat HealthCare acquires Hilltop Drugs Etc

Kubat Healthcare | May 10, 2022

Kubat HealthCare, a leading health care service provider, announces today the acquisition of Hilltop Drugs Etc located at 108 W 11th St in Neligh, Nebraska 68756. Founded in October 2008 by co-founder and current Pharmacist-In-Charge, Jami Schmidt, Hilltop Drugs Etc quickly became a community staple providing personalized pharmacy and healthcare services. In 2019, Jami Schmidt and her business partner sold to Mark Vogt. "When I started Hilltop Drugs Etc in 2008, I wanted to provide the community with exceptional pharmacy solutions," said Jami Schmidt, who will remain as the Pharmacist-In-Charge, "I am thrilled that by joining with Kubat HealthCare, not only will our community continue to have pharmacy needs met, but we will now be able to offer additional health care services that have not been made available until now." By joining the Kubat HealthCare family, Neligh and surrounding communities will benefit from the access to respiratory care, specialized compounded medications, infusion, and home medical equipment solutions through their other locations in Nebraska. Hilltop Drugs Etc will continue to offer home delivery and mailing of patient's prescriptions, RediMedi compliance packaging, vaccinations, and assistance with enrolling in Medicare Part D prescription insurance plans. "The team at Hilltop Drugs is exceptional. While the name will change in the coming months, we are ecstatic to have Jami Schmidt and the team continue to provide exceptional service to the community." Tony Schmid, Vice President of Pharmacy Operations at Kubat HealthCare At Kubat HealthCare, their growth initiative has been focused on entering communities that have been previously underserved by their healthcare options. "Through our network, our team members are able to provide additional healthcare services to communities throughout the Midwest" said Bret Cain, COO of Kubat HealthCare, "And as we continue to grow, it reassures me that we are creating a beneficial healthcare network of service offerings to deserving communities."

Read More

Spotlight

Global Blockchain in Healthcare Market by Organization Size (Large Enterprises, Small & Medium-sized Enterprises (Sme’s) by Blockchain Type (Public, Private, Hybrid) by Application (Healthcare Data Exchange, Pharmaceuticals Supply Chain, Health Insurance, Drug Discovery, Identity & Authentication, Other Application) & by Geography.

Resources